Solanezumab
Solanezumab
Solanezumab (pronounced so-lan-ez-u-mab) is a monoclonal antibody designed for the treatment of Alzheimer's disease. It is developed by Eli Lilly and Company, a global pharmaceutical company.
Etymology
The name "Solanezumab" is derived from the Latin word "solane", meaning "alone", and "zumab", a suffix used in the names of humanized monoclonal antibodies.
Mechanism of Action
Solanezumab works by binding to the amyloid-beta peptides that form plaques in the brain, a characteristic feature of Alzheimer's disease. This binding is thought to prevent the formation of plaques and promote the clearance of amyloid-beta from the brain.
Clinical Trials
Solanezumab has been tested in several clinical trials, but it has not yet been approved for use in the treatment of Alzheimer's disease. The results of these trials have been mixed, with some showing a slowing of cognitive decline in patients with mild Alzheimer's disease, and others showing no significant effect.
Related Terms
External links
- Medical encyclopedia article on Solanezumab
- Wikipedia's article - Solanezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski